/REMS for new biologic; CMO pair seeks high-volume orders;
NEWS

REMS for new biologic; CMO pair seeks high-volume orders;

FiercePharma
2010/02/15

The FDA has required a risk evaluation and mitigation strategy for Xiaflex, the recently approved biologic from Auxilium Pharmaceuticals. Item

A collaboration between Albemarle Corp. and PharmaCore aims to handle projects that require high-volume capacity. Release

East African nations are considering counterfeit-drug legislation that threatens generics--to India's dismay. Article

Formatech is celebrating the issuance of U.S. patent 7,659,310, "Methods of Enhancing Solubility of Agents," which covers novel formulation methods for hydrophobic compounds. Release

The $20-million Abacus Parenteral Drug facility in Mukono, Uganda, is up and running, yielding cheaper drugs and displacing imports from Europe and India. Article

Summary

> The FDA has required a risk evaluation and mitigation strategy for Xiaflex, the recently approved biologic from Auxilium Pharmaceuticals. Item > A collaboration between Albemarle Corp. and